| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor with potential for Canine and Feline Mammary Cancer via Activation of the Endoplasmic Reticulum Stress Pathway. BB-Cl-Amidine is a modified version of Cl-amidine that retains the functional components but possesses a C-terminal benzimidazole group designed to limit proteolysis of the C-terminal amide. BB-CLA reduced viability and tumorigenicity of canine and feline mammary cancer cell lines in vitro. BB-CLA activates the endoplasmic reticulum stress pathway in these cells by downregulating 78 kDa Glucose-regulated Protein (GRP78), a potential target in breast cancer for molecular therapy, and upregulating the downstream target gene DNA Damage Inducible Transcript 3 (DDIT3).
| ln Vivo |
In MRL/lpr animals, therapy with BB-Cl-amidine somewhat decreased splenomegaly, but treatment with PAD inhibitors tended to raise the amount of anti-NET antibodies in circulation. Nevertheless, body weight and total IgG levels were unaffected by any of the PAD inhibitors. Cl-amidine and BB-Cl-amidine therapy actually greatly enhanced endothelium-dependent vasodilation. Additionally, there was a clear tendency of IRG downregulation in the BB-Cl-amidine group. Cl-amidine or BB-Cl-amidine therapy can considerably lessen oral hair loss and, in many situations, stop it altogether [1].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: MRL/lpr mouse[1].
Doses: 1 mg/kg. Route of Administration: Administer subcutaneously (sc) (sc) daily from 8 to 14 weeks of age. Experimental Results: Endothelium-dependent vasodilation was Dramatically improved and demonstrated a strong trend of IRG downregulation. |
| References |
| Molecular Formula |
C₂₆H₂₆CLN₅O
|
|---|---|
| Molecular Weight |
459.97
|
| Exact Mass |
459.182
|
| Elemental Analysis |
C, 67.89; H, 5.70; Cl, 7.71; N, 15.23; O, 3.48
|
| CAS # |
1802637-39-3
|
| Related CAS # |
BB-Cl-Amidine hydrochloride;2436747-41-8
|
| PubChem CID |
129021946
|
| Appearance |
Solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.655
|
| LogP |
3.86
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
33
|
| Complexity |
645
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
ClC/C(/N)=N\CCC[C@@H](C1=NC2C=CC=CC=2N1)NC(C1C=CC(C2C=CC=CC=2)=CC=1)=O
|
| InChi Key |
YDOAWJHYHGBQFI-QHCPKHFHSA-N
|
| InChi Code |
InChI=1S/C26H26ClN5O/c27-17-24(28)29-16-6-11-23(25-30-21-9-4-5-10-22(21)31-25)32-26(33)20-14-12-19(13-15-20)18-7-2-1-3-8-18/h1-5,7-10,12-15,23H,6,11,16-17H2,(H2,28,29)(H,30,31)(H,32,33)/t23-/m0/s1
|
| Chemical Name |
N-[(1S)-1-(1H-benzimidazol-2-yl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-[1,1'-biphenyl]-4-carboxamide
|
| Synonyms |
BB-Cl-Amidine BB-CLA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~271.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.52 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1741 mL | 10.8703 mL | 21.7405 mL | |
| 5 mM | 0.4348 mL | 2.1741 mL | 4.3481 mL | |
| 10 mM | 0.2174 mL | 1.0870 mL | 2.1741 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
